Home
NICE Guidance
Published Guidance

Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab

Technology appraisal guidance [TA472] Published: 30 August 2017

Guidance

This guidance has been updated and replaced by NICE technology appraisal guidance 629.